Trial Profile
A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Oct 2009 Actual patient number changed from 260 to 261 as reported by ClinicalTrials.gov.
- 28 Jul 2009 Results presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), 2009.
- 24 Feb 2009 Actual patient numbers (260) added as reported by ClinicalTrials.gov.